2026 ACC/AHA Clinical Performance and Quality Measures for Patients With Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Performance Measures
Abstract
This document describes the 2026 ACC/AHA Clinical Performance and Quality Measures for Patients With Peripheral Artery Disease, which were developed to guide clinicians, researchers, quality assurance personnel, payers, and regulatory agencies in the care of individuals with peripheral artery disease. The measures are designed to enable the assessment of the effects of treatment decisions, such as which medications should be used for individuals with peripheral artery disease and which tests are appropriate for follow-up after treatment interventions. The goal of this document is to help ensure that evidence-based care is offered to individuals with peripheral artery disease, and this care can be measured reliably and reproducibly across myriad care settings and populations.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.